AKT1 and cancer: These findings not only provide a potential molecular explanation for the enhanced cisplatin-killing effect on the cancer cells by VitD, but also suggest the further experimental exploitation of additional cotreatment combinations such as using mTOR and Akt inhibitors in combination with VitD.